Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China
C Wang, L Su, Q Mu, X Gu, X Guo… - Human Vaccines & …, 2021 - Taylor & Francis
ABSTRACT Background: The first Chinese domestic 13-valent pneumococcal conjugate
vaccine (WoAnxin®, PCV-13) is available for children aged 2 months to 5 years and is more …
vaccine (WoAnxin®, PCV-13) is available for children aged 2 months to 5 years and is more …
The cost-effectiveness of 13-valent pneumococcal conjugate vaccine in seven chinese cities
Y Li, H Wang, W Furnback, BCM Wang, S Zhu, P Dong - Vaccines, 2021 - mdpi.com
Objective: This study estimates the cost-effectiveness of vaccination with the 13-valent
pneumococcal conjugate vaccine (PCV13) among infants in Beijing, Shanghai, Shenzhen …
pneumococcal conjugate vaccine (PCV13) among infants in Beijing, Shanghai, Shenzhen …
[HTML][HTML] Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study
Abstract Background Streptococcus pneumoniae (Spn) is a common respiratory pathogen
and the main cause of bacterial pneumonia, meningitis, and bacteremia, acute otitis media …
and the main cause of bacterial pneumonia, meningitis, and bacteremia, acute otitis media …
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double …
W Wang, Q Liang, J Zhu, J Zhang, J Chen… - Human Vaccines & …, 2022 - Taylor & Francis
This study aimed to evaluate the immunogenicity and safety of a 13-valent pneumococcal
conjugate vaccine (PCV13). In total, 1200 infants were randomized into two groups with a 1 …
conjugate vaccine (PCV13). In total, 1200 infants were randomized into two groups with a 1 …
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines–a systematic review and network meta-analysis
S Feng, J McLellan, N Pidduck, N Roberts, JPT Higgins… - medRxiv, 2023 - medrxiv.org
Background Vaccination of infants with pneumococcal conjugate vaccines (PCV) is
recommended by the World Health Organisation. Evidence is mixed regarding the …
recommended by the World Health Organisation. Evidence is mixed regarding the …
[HTML][HTML] 肺炎球菌性疾病免疫预防专家共识(2020 版)
Chinese Preventive Medicine Association - 中华流行病学杂志, 2020 - html.rhhz.net
肺炎球菌性疾病是全球严重的公共卫生问题之一, 也是导致中国儿童及成年人发病和死亡的重要
原因. 肺炎球菌性疾病的临床治疗用药以抗生素为主, 由于抗生素的广泛应用 …
原因. 肺炎球菌性疾病的临床治疗用药以抗生素为主, 由于抗生素的广泛应用 …
Pneumococcal vaccination for developing countries: PCV10 or PCV13?
EB Temple - 2023 - researchonline.lshtm.ac.uk
Streptococcus pneumoniae (pneumococcus) is the most common cause of pneumonia and
a major cause of meningitis globally. Pneumococcal conjugate vaccines (PCVs) offer …
a major cause of meningitis globally. Pneumococcal conjugate vaccines (PCVs) offer …
Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual …
S Feng, J McLellan, N Pidduck, N Roberts… - …, 2023 - thelancet.com
Background Vaccination of infants with pneumococcal conjugate vaccines (PCV) is
recommended by the World Health Organization. Evidence is mixed regarding the …
recommended by the World Health Organization. Evidence is mixed regarding the …